Laboratorios Rovi : CMD 2022: gloomy FY23 outlook on limited COVID vaccine visibility and slow progression of key pipeline treatments
>Dull CMD with limited new material - A rather uneventful CMD: the gloomy FY23 guidance was maintained and the key pipeline elements are progressing rather slower than expected. The most notable takeaway was Rovi stating that they ‘will not be shy’ if a partner approaches them to codevelop the (likely) expensive ph II for Letrozole. We think the lack of a relevant (positive) highlight in Rovi’s CMD has led the stock to shed most of the 11% bounce-back seen after the l...Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.